MBII Marrone Bio Innovations Inc

Marrone Bio Innovations to Present at Upcoming Investor Conferences

Marrone Bio Innovations to Present at Upcoming Investor Conferences

DAVIS, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (the “Company” or “MBI”) (NASDAQ: MBII), a leading developer of bio-based products for pest management and plant health, today announced that management will attend several investor conferences in San Francisco and New York throughout September 2019.

Management of Marrone Bio Innovations will host one-on-one meetings throughout the day at the H.C. Wainwright 21st Annual Global Investment Conference and is scheduled to present as follows:

LD Micro SF Summit      

Date: Tuesday, September 3, 2019

Speaker: Jim Boyd, Chief Financial Officer

Presentation Time: 10:00 a.m. Pacific time          

Location: San Francisco, California

               

H.C. Wainwright 21st Annual Global Investment Conference      

Date: Monday, September 9, 2019

Speaker: Pam Marrone, Chief Executive Officer

Presentation Time: 10:00 a.m. Eastern time        

Location: Lotte New York Palace Hotel (455 Madison Ave, New York, NY 10022)

Sustainable Investment Forum North America  

Date: Wednesday, September 25, 2019

Attendee: Pam Marrone, Chief Executive Officer

Format: Attendee only (No presentation)            

Location: Crowne Plaza Hotel (1605 Broadway, New York, NY 10019)

Diamond Equity Research Emerging Growth Invitational

Date:
Wednesday, September 25, 2019

Speaker: Pam Marrone, Chief Executive Officer

Event Time: 6:00 – 9:30 p.m. Eastern time

Location: The Cornell Club (6 East 44th Street, New York, NY 10017)

Conference participation is by invitation only and registration is mandatory. For more information or to schedule a one-on-one meeting, please contact your conference representative.

About Marrone Bio Innovations               

 (NASDAQ: MBII) is a growth-oriented company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the company’s product pipeline.

Learn more about Marrone Bio Innovations at . Follow us on social media: ,  and .

Marrone Bio Innovations Contacts:        

Pam Marrone, CEO and Founder              

Telephone: +1 (530) 750-2800    

Email:    

Investor Relations:         

Greg Falesnik    

Managing Director          

MZ Group – MZ North America 

Main: 949-385-6449        

          

           

EN
28/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Marrone Bio Innovations Inc

 PRESS RELEASE

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement wi...

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI’s stockholde...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Res...

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the ...

 PRESS RELEASE

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednes...

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations’ first quarter financial re...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 202...

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was ...

 PRESS RELEASE

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Cr...

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), has signed an agreement with Corteva Agriscience (NYSE: CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. MBI introduced biological seed treatments as a sustainable alternative to control yield-robbing pests in the United States i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch